Robert Kottmann, MD
Pulmonary Disease · Rochester, NYNPI 1073620738
Payments from drug & device makers
What this record shows
This record is dominated by education: $52 of the $52 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, CSL Behring. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.
Across 2 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$52
Across 79 payments — averaging $11,550 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$492K
- United Therapeutics Corporation$223K
- UCB SA$198K
What the payments were for
- Education$52100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 2 | $52 |
How this compares
$52 in reported general payments places this provider in the 15th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 61 | $748,730 |
| Pirfenidone | 30 | $122,035 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,334 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $10,818 |
| Tiotropium Bromide | 12 | $3,841 |
| Methylprednisolone | 31 | $3,012 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $877 |
| Mycophenolate Mofetil | 17 | $831 |
| MethotrexateMethotrexate Sodium | 17 | $249 |
| Prednisone | 57 | $167 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $109 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Rochester
- R WhiteRochester$242K
- Michael LarjRochester$229K
- Daniel LachantRochester$141K
- Jason LyonsRochester$55K
- Christina BachRochester$53K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.